Profile data is unavailable for this security.
About the company
Solasia Pharma KK is a Japan-based company with a product development pipeline of pharmaceuticals and medical devices, and is engaged in the development and sale of pharmaceuticals. Its main business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events caused by the administration of malignant tumor treatment drugs and radiation therapy, and improve the treatment of malignant tumors and the quality of life (QOL) of patients. It is engaged in in-licensing of rights for pharmaceutical or medical device candidate substances, development of pharmaceutical candidates, and monetization of pharmaceutical candidates. Its development pipeline includes the transdermal granisetron preparation Sancuso, the organic arsenic preparation darinaparsin, the oral wound dressing protective material episil, and the intracellular superoxide remover PledOx.
- Revenue in JPY (TTM)159.00m
- Net income in JPY-1.29bn
- Incorporated2007
- Employees24.00
- LocationSolasia Pharma KK3F, Shiodome Bldg., 1-2-20, KaiganMINATO-KU 105-0011JapanJPN
- Phone+81 358438045
- Fax+81 367212020
- Websitehttps://solasia.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NIPPON CHEMIPHAR CO., LTD. | 31.21bn | -133.00m | 6.84bn | 887.00 | -- | 0.3152 | 5.29 | 0.2193 | -36.85 | -36.85 | 8,647.86 | 5,095.28 | 0.6053 | 2.06 | 2.79 | 35,182,640.00 | -0.258 | 0.7482 | -0.3663 | 1.08 | 25.57 | 30.99 | -0.4262 | 1.13 | 1.53 | -- | 0.4954 | 50.73 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
COSMO BIO COMPANY, LIMITED | 9.64bn | 339.00m | 6.97bn | 155.00 | 19.83 | 0.7339 | 14.19 | 0.7226 | 58.08 | 58.08 | 1,651.14 | 1,569.72 | 0.8536 | 6.07 | 3.81 | 62,206,450.00 | 3.11 | 5.62 | 3.62 | 6.72 | 33.17 | 37.40 | 3.64 | 6.23 | 6.28 | -- | 0.002 | 33.53 | -2.23 | 5.16 | -14.51 | 11.20 | -8.03 | 16.47 |
Wakamoto Pharmaceutical Co Ltd | 7.76bn | -3.16m | 8.74bn | 274.00 | -- | 0.7259 | 21.36 | 1.13 | -0.0911 | -0.0911 | 223.67 | 345.76 | 0.5017 | 2.07 | 2.98 | 28,330,810.00 | -0.0205 | -2.28 | -0.0233 | -2.64 | 47.07 | 51.00 | -0.0408 | -3.97 | 3.64 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
Perseus Proteomics Inc | 96.49m | -901.50m | 9.10bn | 25.00 | -- | 4.61 | -- | 94.34 | -74.89 | -74.89 | 8.00 | 134.05 | 0.0443 | 3.21 | 11.84 | 3,859,520.00 | -41.36 | -41.34 | -43.27 | -43.43 | 87.73 | 91.72 | -934.32 | -891.26 | 19.91 | -- | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
Solasia Pharma KK | 159.00m | -1.29bn | 9.16bn | 24.00 | -- | 4.26 | -- | 57.63 | -7.36 | -7.36 | 0.9065 | 9.85 | 0.0639 | 0.8549 | 0.5256 | 6,625,000.00 | -51.68 | -48.57 | -59.50 | -58.83 | 31.45 | 71.01 | -808.81 | -300.89 | 3.42 | -61.24 | 0.0219 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 9.20bn | 159.00 | -- | 1.79 | -- | -- | -- | -- | -- | 1,003.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.82 | -- | 0.2942 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
K Pharma Inc | 0.00 | -680.95m | 9.26bn | 15.00 | -- | 3.46 | -- | -- | -58.58 | -58.58 | 0.00 | 230.79 | 0.00 | 0.00 | -- | 0.00 | -27.16 | -- | -29.66 | -- | -- | -- | -- | -- | 34.85 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
ReproCell Inc | 2.49bn | -178.74m | 10.57bn | 96.00 | -- | 1.20 | -- | 4.24 | -2.03 | -2.03 | 28.72 | 93.57 | 0.2826 | 4.76 | 6.63 | 25,940,160.00 | -2.03 | -7.35 | -2.20 | -8.00 | 48.99 | 39.83 | -7.18 | -27.16 | 9.99 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
RaQualia Pharma Inc | 2.30bn | -673.00m | 10.86bn | 67.00 | -- | 1.92 | -- | 4.73 | -31.12 | -31.12 | 106.28 | 261.02 | 0.2652 | 3.82 | 2.89 | 34,300,980.00 | -7.77 | 2.13 | -8.56 | 2.26 | 84.78 | 88.49 | -29.28 | 5.32 | 3.55 | -- | 0.3972 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
Symbio Pharmaceuticals Ltd | 3.70bn | -3.42bn | 11.20bn | 109.00 | -- | 1.73 | -- | 3.03 | -81.51 | -81.51 | 87.41 | 140.73 | 0.4494 | 2.89 | 4.74 | 33,903,380.00 | -41.64 | -19.18 | -46.17 | -23.62 | 79.40 | 65.84 | -92.66 | -24.32 | 9.01 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
Ohki Healthcare Holdings Co Ltd | 340.31bn | 2.08bn | 12.50bn | 632.00 | 5.86 | 0.4275 | 5.26 | 0.0367 | 151.56 | 151.56 | 24,771.52 | 2,077.28 | 2.54 | 13.31 | 4.54 | 538,470,000.00 | 1.49 | 1.85 | 6.44 | 8.42 | 5.11 | 6.16 | 0.5859 | 0.7178 | 0.8853 | -- | 0.1698 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
Oncolys Biopharma Inc | 31.38m | -1.82bn | 12.60bn | 34.00 | -- | 8.13 | -- | 401.40 | -95.02 | -95.02 | 1.62 | 67.90 | 0.0167 | 0.00 | 0.2245 | 923,058.80 | -97.25 | -45.75 | -116.54 | -51.86 | 0.00 | 60.46 | -5,813.82 | -233.66 | 7.01 | -- | 0.2052 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
Holder | Shares | % Held |
---|---|---|
Macquarie Bank Ltd. (Private Banking)as of 22 Jul 2024 | 5.76m | 2.92% |
Rheos Capital Works, Inc. (Investment Management)as of 30 Sep 2022 | 2.32m | 1.18% |
Simplex Asset Management Co., Ltd.as of 04 Jul 2024 | 835.10k | 0.42% |